Prostate specific antigen (PSA) is a biomarker for prostate cancer. Here, the authors develop a mathematical model where longitudinal changes in PSA levels predict responses to intermittent androgen deprivation in patients with prostate cancer.
- Renee Brady-Nicholls
- John D. Nagy
- Heiko Enderling